Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Pharmacology, Toxicology and Pharmaceutical Science
28
9%
Immunology and Microbiology
22
7%
Biochemistry, Genetics and Molecular Biology
16
5%
Nursing and Health Professions
8
3%
Other
15
5%
Unknown
134
45%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 281. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2026.
All research outputs
#160,223
of 34,457,357 outputs
Outputs from Infectious Diseases and Therapy
#9
of 1,075 outputs
Outputs of similar age
#2,636
of 385,919 outputs
Outputs of similar age from Infectious Diseases and Therapy
#1
of 12 outputs
Altmetric has tracked 34,457,357 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,075 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 385,919 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.
